title: Pathologic complete response of advanced ovarian mixed mesodermal tumor to cisplatin, adriamycin and dacarbazine: a case report.
abstract: Presented is a case report of a stage IIIC primary ovarian mixed mesodermal tumor with gross residual disease following aggressive cytoreductive surgery. Following twelve courses of Cisplatin, Adriamycin and Dacarbazine, second-look laparotomy confirmed a pathologic complete response. The patient is now free of disease at 17+ months.
authors.affiliation: Dept. of Gynecology Oncology, Roswell Park Memorial Institute, Buffalo.
authors.forename: J
authors.initials: J
authors.lastname: Fanning
authors.forename: S
authors.initials: S
authors.lastname: Zylstra
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukada
authors.forename: M S
authors.initials: MS
authors.lastname: Piver
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003606:Dacarbazine; D004317:Doxorubicin; D002945:Cisplatin